NorthStar Medical Radioisotopes parent NorthStar Medical Technologies has signed a letter of intent to supply radiopharmaceutical firm Clarity Pharmaceuticals with copper-67 (Cu-67).
Under the deal, NorthStar will provide Clarity with the beta-emitting radioisotope as an active pharmaceutical ingredient for the company's pipeline of copper-based radiopharmaceuticals. NorthStar said it will be a major U.S. supplier of Cu-67 for Clarity, which is developing targeting agents for potential treatment of neuroblastoma, prostate, breast, and ovarian cancers.
